Combination of hydralazine and isosorbide dinitrate

Revision as of 18:16, 18 September 2021 by Mitra Chitsazan (talk | contribs) (/* Combination of Hydralazine and Nitrates in Patients Presenting With Heart Failure (DO NOT EDIT) Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guid...)
Jump to navigation Jump to search

2009 ACC/AHA Focused Update and 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult (DO NOT EDIT) [1][2]

Combination of Hydralazine and Nitrates in Patients Presenting With Heart Failure (DO NOT EDIT) [1][2]

Class I
"1. The combination of fixed-dose of isosorbide dinitrate and hydralazine to a standard medical regimen for HF, including ACE inhibitors and beta blockers, is recommended in order to improve outcomes for patients self-described as African Americans, with NYHA functional class III or IV HF Others may benifit similarly, but this has not yet been tested.[3][4] (Level of Evidence: A) "
Class IIa
"1. The addition of a combination of hydralazine and a nitrate is reasonable for patients with reduced left ventricular ejection fraction (LVEF) who are already taking an ACE inhibitor and beta blocker for symptomatic heart failure and who have persistent symptoms.[4][5] (Level of Evidence: B) "
Class IIb
"1. A combination of hydralazine and a nitrate might be reasonable in patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF) who cannot be given an ACE inhibitor or ARB because of drug intolerance, hypotension, or renal insufficiency. [4][6][7] (Level of Evidence: C) "
  1. ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202
  2. ↑ 2.0 2.1 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967
  3. ↑ Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN (2004). "Combination of isosorbide dinitrate and hydralazine in blacks with heart failure". The New England Journal of Medicine. 351 (20): 2049–57. doi:10.1056/NEJMoa042934. PMID 15533851. Retrieved 2012-04-05. Unknown parameter |month= ignored (help)
  4. ↑ 4.0 4.1 4.2 Carson P, Ziesche S, Johnson G, Cohn JN (1999). "Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group". Journal of Cardiac Failure. 5 (3): 178–87. PMID 10496190. Retrieved 2012-04-05. Unknown parameter |month= ignored (help)
  5. ↑ Cohn JN (1993). "The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction". Circulation. 87 (6 Suppl): VI1–4. PMID 8500232. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  6. ↑ Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH (1986). "Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study". The New England Journal of Medicine. 314 (24): 1547–52. doi:10.1056/NEJM198606123142404. PMID 3520315. Retrieved 2012-04-05. Unknown parameter |month= ignored (help)
  7. ↑ Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN (1993). "Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group". Circulation. 87 (6 Suppl): VI78–87. PMID 8500244. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
Retrieved from "https://www.wikidoc.org/index.php?title=Combination_of_hydralazine_and_isosorbide_dinitrate&oldid=1714258"